Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.180 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 944,530
Open 7.230
Bid (Size) 7.000 (300)
Ask (Size) 7.300 (300)
Prev. Close 7.180
Today's Range 7.100 - 7.240
52wk Range 3.140 - 10.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗
Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance. 
Via Chartmill

Performance

YTD
+107.5%
+107.5%
1 Month
-25.4%
-25.4%
3 Month
-8.3%
-8.3%
6 Month
+45.3%
+45.3%
1 Year
+118.9%
+118.9%

More News

Read More
News headline image
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
Via Benzinga
News headline image
Earnings Outlook For Xeris Biopharma Holdings ↗
Via Benzinga
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris (XERS) Q2 Revenue Jumps 49% ↗
Via The Motley Fool
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
Via Chartmill
News headline image
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Details for Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template ↗
Via Chartmill
News headline image
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick? ↗
Via Chartmill
News headline image
Xeris Announces Changes to Its Board of Directors
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
From Xeris Biopharma Holdings, Inc.
Via Business Wire

Frequently Asked Questions

Is Xeris Biopharma Holdings, Inc. - Common Stock publicly traded?
Yes, Xeris Biopharma Holdings, Inc. - Common Stock is publicly traded.
What exchange does Xeris Biopharma Holdings, Inc. - Common Stock trade on?
Xeris Biopharma Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock?
The ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock is XERS on the Nasdaq Stock Market
What is the current price of Xeris Biopharma Holdings, Inc. - Common Stock?
The current price of Xeris Biopharma Holdings, Inc. - Common Stock is 7.180
When was Xeris Biopharma Holdings, Inc. - Common Stock last traded?
The last trade of Xeris Biopharma Holdings, Inc. - Common Stock was at 11/28/25 01:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.